Department of Oncology, Division of Chemotherapy, the People's Hospital of Baise, Baise, 533000, People's Republic of China.
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, People's Republic of China.
Radiat Oncol. 2018 Nov 20;13(1):226. doi: 10.1186/s13014-018-1177-9.
The value of postoperative radiotherapy in tubular breast carcinoma patients under 65 years is uncertain.
Data on patients with estrogen receptor positive T1N0M0 tubular breast carcinoma who were younger than 65 years and who received breast-conserving surgery between 2000 and 2013 were retrieved from the Surveillance, Epidemiology and End Results database. Demographic, clinicopathologic features, and receipt of postoperative radiotherapy were analyzed to investigate effects on survival.
Data from 2442 patients were analyzed, of whom 2020 (82.7%) received postoperative radiotherapy and 422 (17.3%) did not. The number of patients treated with or without postoperative radiotherapy showed no differences during the study period (p = 0.184). Radiotherapy was more likely to be administered in patients with well differentiated tumors. Multivariate Cox analysis showed that postoperative radiotherapy delivery was significantly correlated with better breast cancer-specific survival (BCSS) (hazard ratio [HR] 0.297, 95% confidence interval [CI] 0.105-0.836, p = 0.022) and overall survival (OS) (HR 0.656, 95% CI 0.441-0.978, p = 0.038). Ten 10-year BCSS was 99.3% in patients who received postoperative radiotherapy and 98.1% in those who did not (p = 0.020), and 10-year OS was 93.4 and 91.0%, respectively (p = 0.029). Postoperative radiotherapy increased BCSS and OS in the subgroups of age < 50 years, non-Hispanic white, well differentiated tumors, and progesterone receptor positive tumors.
Postoperative radiotherapy after breast-conserving surgery improved survival outcomes in tubular breast carcinoma patients aged < 50 years. However, omitting postoperative radiotherapy may not decrease survival in patients aged ≥50 years.
65 岁以下管状乳腺癌患者术后放疗的价值尚不确定。
从监测、流行病学和最终结果数据库中检索了 2000 年至 2013 年间接受保乳手术且年龄小于 65 岁、雌激素受体阳性 T1N0M0 管状乳腺癌患者的数据。分析了人口统计学、临床病理特征以及接受术后放疗的情况,以研究对生存的影响。
共分析了 2442 例患者的数据,其中 2020 例(82.7%)接受了术后放疗,422 例(17.3%)未接受。研究期间接受或未接受术后放疗的患者数量无差异(p=0.184)。分化良好的肿瘤患者更有可能接受放疗。多因素 Cox 分析显示,术后放疗与更好的乳腺癌特异性生存(BCSS)显著相关(风险比[HR]0.297,95%置信区间[CI]0.105-0.836,p=0.022)和总生存(OS)(HR 0.656,95% CI 0.441-0.978,p=0.038)。接受术后放疗的患者 10 年 BCSS 为 99.3%,未接受的患者为 98.1%(p=0.020),10 年 OS 分别为 93.4%和 91.0%(p=0.029)。术后放疗增加了年龄<50 岁、非西班牙裔白人、分化良好肿瘤和孕激素受体阳性肿瘤亚组的 BCSS 和 OS。
保乳手术后的术后放疗改善了<50 岁管状乳腺癌患者的生存结果。然而,在年龄≥50 岁的患者中,省略术后放疗可能不会降低生存率。